US patent for Evoqua BWMS

The patent describes a technical solution for treating ballast water under a variety of ambient water qualities. The quality of ambient water can vary widely from port to port where the ship is taking on its ballast.

Evoqua’s SeaCure system uses oxidation reduction potential (“ORP”) devices to control certain system operations. The patented system takes into account variations in demand and delivers biocide at the dose necessary for successful biofouling control, while minimising unwanted side effects such as formation of disinfection byproducts and corrosion.

Evoqua says the system employs low-maintenance, easy to handle probes that measure the oxidising potential of the water in both the sea chest and the ballast tank as. These data govern the addition or concentration of biocide introduced into the shipboard cooling water system, a process that saves energy and reduces operating costs according to the company.

The SeaCure BWMS employs filtration and electrolysis from seawater to eliminate organisms, using agents mixed onboard, rather than having to pay to stock them on the vessel. Electrolysis is carried out using Evoqua’s Chloropac self-cleaning concentric tubular electrodes.

Ian Stentiford, global vice president for electrocatalytic products, Evoqua said: The SeaCURE system is currently being extensively tested in the US laboratories for US Coast Guard type approval to give our customers further peace of mind”